Im Cannabis Corp (IMCC)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
IMCC
Im Cannabis Corp
$0.12
+0.26%
HEALTHCARE · Cap: $1.09M
TAK
Takeda Pharmaceutical Co Ltd ADR
$17.09
-0.93%
HEALTHCARE · Cap: $55.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 8850264% more annual revenue ($4.51T vs $50.91M). TAK leads profitability with a -3.4% profit margin vs -27.3%. TAK earns a higher WallStSmart Score of 57/100 (C).
IMCC
Avoid31
out of 100
Grade: F
TAK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+20.3%
Fair Value
$1.48
Current Price
$0.12
$1.36 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -119.8% — below average capital efficiency
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : IMCC
The strongest argument for IMCC centers on Debt/Equity.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.
Bear Case : IMCC
The primary concerns for IMCC are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
IMCC carries more volatility with a beta of 2.04 — expect wider price swings.
TAK is growing revenue faster at 3.9% — sustainability is the question.
IMCC generates stronger free cash flow (-191,000), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TAK scores higher overall (57/100 vs 31/100). IMCC offers better value entry with a 20.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Im Cannabis Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
IM Cannabis Corp. The company is headquartered in Tel Aviv-Yafo, Israel.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?